ration engine has enabled ARIUS to assemble a portfolio
of more than 500 antibody candidates. In addition to the antibodies it is
developing in-house, ARIUS has ongoing partnerships with key biotechnology
and drug development companies. ARIUS is listed on the TSX under the symbol
"ARI". For further information, visit
http://www.ariusmabs.com
Financial Information to Follow:
ARIUS RESEARCH INC.
(A DEVELOPMENT STAGE COMPANY)
INTERIM BALANCE SHEETS
(Unaudited)
-------------------------------------------------------------------------
February 29, November 30,
2008 2007
$ $
-------------------------------------------------------------------------
Assets
Current assets:
Cash and cash equivalents 9,760,273 5,635,365
Short-term investments 1,299,844 6,825,190
Receivables 197,542 230,126
Refundable tax credits 549,139 400,000
Prepaid expenses 341,826 387,674
-----------------------------------------------------------------------
12,148,624 13,478,355
Facilities and equipment, net 1,807,824 1,889,921
-------------------------------------------------------------------------
13,956,448 15,368,276
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Cur
'/>"/>
SOURCE ARIUS Research Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Arius Features Preclinical Data on Antibody Candidates at Two Conferences2.
ARIUS Announces Third Quarter Fiscal 2007 Financial Results3.
Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference4.
ARIUS to present at Chinese Global Financial Forum5.
ARIUS announces cancer stem cell antibody program successfully completes first toxicology study6.
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs7.
ARIUS to present at BioNorth Biotechnology and Life Sciences Conference8.
ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody9.
ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call10.
Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program11.
ARIUS announces fourth quarter and year-end fiscal 2007 financial results